Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS/FTD.
Amyotrophic lateral sclerosis
CRISPR
DNA damage
DNA double strand break repair
Homology-directed repair
Induced pluripotent stem cells
RAD52
Single-strand annealing
Journal
Molecular neurodegeneration
ISSN: 1750-1326
Titre abrégé: Mol Neurodegener
Pays: England
ID NLM: 101266600
Informations de publication
Date de publication:
24 02 2020
24 02 2020
Historique:
received:
17
07
2019
accepted:
13
02
2020
entrez:
26
2
2020
pubmed:
26
2
2020
medline:
20
3
2021
Statut:
epublish
Résumé
The C9ORF72 hexanucleotide repeat expansion is the most common known genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), two fatal age-related neurodegenerative diseases. The C9ORF72 expansion encodes five dipeptide repeat proteins (DPRs) that are produced through a non-canonical translation mechanism. Among the DPRs, proline-arginine (PR), glycine-arginine (GR), and glycine-alanine (GA) are the most neurotoxic and increase the frequency of DNA double strand breaks (DSBs). While the accumulation of these genotoxic lesions is increasingly recognized as a feature of disease, the mechanism(s) of DPR-mediated DNA damage are ill-defined and the effect of DPRs on the efficiency of each DNA DSB repair pathways has not been previously evaluated. Using DNA DSB repair assays, we evaluated the efficiency of specific repair pathways, and found that PR, GR and GA decrease the efficiency of non-homologous end joining (NHEJ), single strand annealing (SSA), and microhomology-mediated end joining (MMEJ), but not homologous recombination (HR). We found that PR inhibits DNA DSB repair, in part, by binding to the nucleolar protein nucleophosmin (NPM1). Depletion of NPM1 inhibited NHEJ and SSA, suggesting that NPM1 loss-of-function in PR expressing cells leads to impediments of both non-homologous and homology-directed DNA DSB repair pathways. By deleting NPM1 sub-cellular localization signals, we found that PR binds NPM1 regardless of the cellular compartment to which NPM1 was directed. Deletion of the NPM1 acidic loop motif, known to engage other arginine-rich proteins, abrogated PR and NPM1 binding. Using confocal and super-resolution immunofluorescence microscopy, we found that levels of RAD52, a component of the SSA repair machinery, were significantly increased iPSC neurons relative to isogenic controls in which the C9ORF72 expansion had been deleted using CRISPR/Cas9 genome editing. Western analysis of post-mortem brain tissues confirmed that RAD52 immunoreactivity is significantly increased in C9ALS/FTD samples as compared to controls. Collectively, we characterized the inhibitory effects of DPRs on key DNA DSB repair pathways, identified NPM1 as a facilitator of DNA repair that is inhibited by PR, and revealed deficits in homology-directed DNA DSB repair pathways as a novel feature of C9ORF72-related disease.
Sections du résumé
BACKGROUND
The C9ORF72 hexanucleotide repeat expansion is the most common known genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), two fatal age-related neurodegenerative diseases. The C9ORF72 expansion encodes five dipeptide repeat proteins (DPRs) that are produced through a non-canonical translation mechanism. Among the DPRs, proline-arginine (PR), glycine-arginine (GR), and glycine-alanine (GA) are the most neurotoxic and increase the frequency of DNA double strand breaks (DSBs). While the accumulation of these genotoxic lesions is increasingly recognized as a feature of disease, the mechanism(s) of DPR-mediated DNA damage are ill-defined and the effect of DPRs on the efficiency of each DNA DSB repair pathways has not been previously evaluated.
METHODS AND RESULTS
Using DNA DSB repair assays, we evaluated the efficiency of specific repair pathways, and found that PR, GR and GA decrease the efficiency of non-homologous end joining (NHEJ), single strand annealing (SSA), and microhomology-mediated end joining (MMEJ), but not homologous recombination (HR). We found that PR inhibits DNA DSB repair, in part, by binding to the nucleolar protein nucleophosmin (NPM1). Depletion of NPM1 inhibited NHEJ and SSA, suggesting that NPM1 loss-of-function in PR expressing cells leads to impediments of both non-homologous and homology-directed DNA DSB repair pathways. By deleting NPM1 sub-cellular localization signals, we found that PR binds NPM1 regardless of the cellular compartment to which NPM1 was directed. Deletion of the NPM1 acidic loop motif, known to engage other arginine-rich proteins, abrogated PR and NPM1 binding. Using confocal and super-resolution immunofluorescence microscopy, we found that levels of RAD52, a component of the SSA repair machinery, were significantly increased iPSC neurons relative to isogenic controls in which the C9ORF72 expansion had been deleted using CRISPR/Cas9 genome editing. Western analysis of post-mortem brain tissues confirmed that RAD52 immunoreactivity is significantly increased in C9ALS/FTD samples as compared to controls.
CONCLUSIONS
Collectively, we characterized the inhibitory effects of DPRs on key DNA DSB repair pathways, identified NPM1 as a facilitator of DNA repair that is inhibited by PR, and revealed deficits in homology-directed DNA DSB repair pathways as a novel feature of C9ORF72-related disease.
Identifiants
pubmed: 32093728
doi: 10.1186/s13024-020-00365-9
pii: 10.1186/s13024-020-00365-9
pmc: PMC7041170
doi:
Substances chimiques
C9orf72 Protein
0
C9orf72 protein, human
0
Dipeptides
0
NPM1 protein, human
0
Nuclear Proteins
0
Nucleophosmin
117896-08-9
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
13Subventions
Organisme : NINDS NIH HHS
ID : R21 NS102829
Pays : United States
Organisme : NIH HHS
ID : R01 NS088689
Pays : United States
Organisme : NIH HHS
ID : U54 NS090291
Pays : United States
Références
Neuron. 2013 Feb 20;77(4):639-46
pubmed: 23415312
Sci Rep. 2012;2:1016
pubmed: 23264878
Science. 2013 Mar 15;339(6125):1335-8
pubmed: 23393093
J Biol Chem. 2013 Apr 5;288(14):9860-6
pubmed: 23423380
Neuron. 2014 Jul 16;83(2):266-282
pubmed: 25033177
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7701-E7709
pubmed: 27849576
Neuron. 2011 Oct 20;72(2):257-68
pubmed: 21944779
Neuron. 2015 Dec 2;88(5):892-901
pubmed: 26637796
Acta Neuropathol Commun. 2017 Apr 18;5(1):29
pubmed: 28420437
Nat Struct Mol Biol. 2011 Nov 27;18(12):1345-50
pubmed: 22120668
Life Sci Alliance. 2018 May 16;1(2):e201800070
pubmed: 30456350
J Biol Chem. 2002 Dec 13;277(50):48234-40
pubmed: 12374805
Cell Res. 2018 Dec;28(12):1127-1128
pubmed: 30367126
Mol Cell Biol. 2004 Feb;24(3):985-96
pubmed: 14729947
Methods Mol Biol. 2012;920:379-91
pubmed: 22941618
J Biol Chem. 2018 Jan 26;293(4):1353-1362
pubmed: 29217771
Acta Neuropathol. 2012 Sep;124(3):339-52
pubmed: 22903397
EMBO J. 2017 Oct 16;36(20):2931-2950
pubmed: 28916614
Neuron. 2014 Dec 17;84(6):1213-25
pubmed: 25521377
Exp Neurol. 2016 Mar;277:171-177
pubmed: 26746986
Neuron. 2016 Oct 19;92(2):383-391
pubmed: 27720481
Acta Neuropathol. 2015 Oct;130(4):537-55
pubmed: 26085200
Proc Natl Acad Sci U S A. 2019 Mar 5;116(10):4696-4705
pubmed: 30770445
Mol Cell. 2010 Oct 22;40(2):216-27
pubmed: 20965417
Nature. 2014 Mar 13;507(7491):195-200
pubmed: 24598541
Microbiol Mol Biol Rev. 2002 Dec;66(4):630-70, table of contents
pubmed: 12456786
Acta Neuropathol. 2013 Dec;126(6):859-79
pubmed: 24096617
Exp Biol Med (Maywood). 2015 Jun;240(6):774-86
pubmed: 25908633
Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4466-71
pubmed: 24616519
J Mol Biol. 2017 Oct 27;429(21):3139-3145
pubmed: 27693651
Acta Neuropathol. 2013 Dec;126(6):881-93
pubmed: 24132570
Nat Cell Biol. 2011 Oct 23;13(11):1376-82
pubmed: 22020440
Nat Med. 2018 Mar;24(3):313-325
pubmed: 29400714
Lancet Neurol. 2012 Apr;11(4):323-30
pubmed: 22406228
Hum Mol Genet. 2015 May 1;24(9):2426-41
pubmed: 25575510
Cell. 2018 Oct 4;175(2):558-570.e11
pubmed: 30245011
Elife. 2016 Nov 09;5:
pubmed: 27828775
Nucleic Acids Res. 2014 Jan;42(1):307-14
pubmed: 24049082
Science. 2007 Sep 21;317(5845):1749-53
pubmed: 17702910
Cold Spring Harb Perspect Med. 2018 Apr 2;8(4):
pubmed: 28130314
Science. 2014 Sep 5;345(6201):1139-45
pubmed: 25081482
Nat Cell Biol. 2005 Aug;7(8):823-30
pubmed: 16041368
Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):10364-9
pubmed: 27562163
J Mol Cell Biol. 2015 Aug;7(4):366-82
pubmed: 25280477
Brain Res. 2014 Oct 10;1584:15-21
pubmed: 24530272
Nat Neurosci. 2015 Sep;18(9):1226-9
pubmed: 26308983
Acta Neuropathol. 2013 Dec;126(6):829-44
pubmed: 24129584
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Mol Cell. 2014 Dec 18;56(6):777-85
pubmed: 25435140
Nat Rev Neurosci. 2016 Jun;17(6):383-95
pubmed: 27150398
Nature. 2014 Nov 20;515(7527):436-9
pubmed: 25186730
Biochem J. 2008 Nov 1;415(3):345-51
pubmed: 18729828
EMBO J. 2011 Jul 29;30(16):3368-82
pubmed: 21804533
PLoS One. 2013 Sep 26;8(9):e75030
pubmed: 24086428
Pediatr Exerc Sci. 2015 May;27(2):219-25
pubmed: 25389217
Cancer Res. 2010 Sep 1;70(17):6746-56
pubmed: 20713529
BMC Mol Biol. 2016 Aug 24;17(1):19
pubmed: 27553022
Hum Mol Genet. 2017 Aug 1;26(15):2882-2896
pubmed: 28481984
Nat Commun. 2018 Mar 15;9(1):1091
pubmed: 29545568
Nature. 2015 Sep 3;525(7567):56-61
pubmed: 26308891
Neuron. 2015 Sep 23;87(6):1207-1214
pubmed: 26402604
Acta Neuropathol. 2015 Jan;129(1):39-52
pubmed: 25388784
FEBS Lett. 2008 Nov 12;582(27):3839-44
pubmed: 18951898
Biochem Res Int. 2011;2011:195209
pubmed: 21152184
Exp Neurol. 2015 Sep;271:241-50
pubmed: 26099177
Int J Mol Sci. 2018 Oct 12;19(10):
pubmed: 30322030
Front Mol Neurosci. 2017 Feb 13;10:35
pubmed: 28243191
Brain. 2018 May 1;141(5):1247-1262
pubmed: 29584802
Lancet. 2016 Aug 27;388(10047):919-31
pubmed: 26987909
Mol Cell Oncol. 2019 Jan 22;6(1):1542244
pubmed: 30788418
Science. 2014 Sep 5;345(6201):1192-1194
pubmed: 25103406
Mol Cell. 2016 Oct 6;64(1):189-198
pubmed: 27716483
Acta Neuropathol. 2019 Jan;137(1):1-26
pubmed: 30368547
Cell. 2016 Oct 20;167(3):774-788.e17
pubmed: 27768896
Acta Neuropathol. 2015 Oct;130(4):559-73
pubmed: 26350237
Mol Cell. 2010 Oct 22;40(2):179-204
pubmed: 20965415
Biochem J. 1995 Feb 1;305 ( Pt 3):987-92
pubmed: 7848301
Mol Neurodegener. 2017 Jun 12;12(1):46
pubmed: 28606110
Cell. 2016 Oct 20;167(3):789-802.e12
pubmed: 27768897
Sci Rep. 2015 Oct 29;5:15709
pubmed: 26511732
J Cell Sci. 2005 Jan 1;118(Pt 1):211-22
pubmed: 15615785
Acta Neuropathol. 2020 Jan;139(1):99-118
pubmed: 31642962
Hum Mol Genet. 2015 Mar 15;24(6):1630-45
pubmed: 25398948
Cell. 2007 Sep 21;130(6):991-1004
pubmed: 17889645
Nat Med. 2004 Jul;10 Suppl:S10-7
pubmed: 15272267
Nat Neurosci. 2013 Oct;16(10):1383-91
pubmed: 24036913
Elife. 2016 Feb 02;5:
pubmed: 26836305
Neuropsychopharmacology. 2003 Jun;28(6):1017-25
pubmed: 12637955
Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1106-1114
pubmed: 25035215
Acta Neuropathol. 2015 Jul;130(1):63-75
pubmed: 25943887
Haematologica. 2007 Apr;92(4):519-32
pubmed: 17488663
Nucleic Acids Res. 2014 Jan;42(2):1180-95
pubmed: 24106084
Nat Neurosci. 2017 Sep;20(9):1225-1235
pubmed: 28714954
Cell Tissue Res. 2018 Aug;373(2):351-360
pubmed: 29450726